Johan Dighed
Director/Board Member at PROMIMIC AB
Network origin in Johan Dighed first degree
Entity | Entity type | Industry | |
---|---|---|---|
Public Company | Financial Conglomerates | 18 | |
11
| Public Company | Medical Specialties | 11 |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021.
7
| Holding Company | Pharmaceuticals: Major | 7 |
KDev Oncology AB
KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden.
7
| Subsidiary | Miscellaneous Commercial Services | 7 |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.
6
| Subsidiary | Pharmaceuticals: Major | 6 |
KD Incentive AB
3
| Subsidiary | 3 | |
KCIF Fund Management AB
3
| Subsidiary | 3 | |
KDev Investments AB
KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden.
3
| Subsidiary | Biotechnology | 3 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Johan Dighed via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Investment Managers | Private Equity Investor Chief Executive Officer Director of Finance/CFO Chief Executive Officer Private Equity Investor Director of Finance/CFO Director of Finance/CFO Director of Finance/CFO | |
Karolinska Institutet | College/University | Doctorate Degree Chairman Doctorate Degree Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree | |
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer Director/Board Member Chief Operating Officer Director/Board Member Chief Tech/Sci/R&D Officer | |
MODUS THERAPEUTICS HOLDING AB | Biotechnology | Chairman Director/Board Member Director/Board Member Director/Board Member Chief Executive Officer | |
University of Uppsala | College/University | Masters Business Admin Doctorate Degree Graduate Degree Graduate Degree Graduate Degree | |
Chalmers University of Technology | College/University | Doctorate Degree Corporate Officer/Principal Graduate Degree Graduate Degree Undergraduate Degree | |
Dilafor AB
Dilafor AB Pharmaceuticals: MajorHealth Technology Dilafor AB develops pharmaceutical products from heparin derivatives with low anticoagulant activity. It investigates document and exploits the pharmacological properties of derivatives in the field of obstetrics. The company was founded by Gunvor Ester Ekman-Ordeberg, Hans-Peter Ekre, Per-Olov Eriksson, Per Giléus, Kjell Gunnarsson, Erik Yngve Holmer, Göran Kvist, Ulf Lindahl, Anders Malmström, Tore Mellstrand, Johan Rasin, and Mats Wahlgren in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Director/Board Member Founder Chairman Director of Finance/CFO | |
SINO BIOPHARMACEUTICAL LIMITED | Pharmaceuticals: Major | Founder Corporate Officer/Principal Chairman Corporate Officer/Principal | |
Stockholm School of Economics | College/University | Undergraduate Degree Masters Business Admin Graduate Degree Masters Business Admin | |
University of Lund | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree Graduate Degree | |
University of Gothenburg | College/University | Masters Business Admin Undergraduate Degree Doctorate Degree Corporate Officer/Principal | |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal | |
invoX Pharma Ltd.
invoX Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., invoX Pharma Ltd. is a British biopharmaceutical company. The company is based in Kingston-upon-Thames, UK. The company was founded in 2021. Benjamin Toogood has been the CEO of the company since 2023. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Chief Investment Officer | |
ONCOPEPTIDES AB | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
Umecrine Cognition AB
Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Director/Board Member Director of Finance/CFO | |
Svenska Vaccinfabriken Produktion AB
Svenska Vaccinfabriken Produktion AB BiotechnologyHealth Technology Svenska Vaccinfabriken Produktion AB develops vaccines and immunotherapies to prevent and treat life-threatening diseases. The company is based in Stockholm, Sweden. The Swedish company was founded by Matti Sällberg, Margaret Chen, Jens Bäck, Lars Frelin. Richard Bethell has been the CEO of the company since 2022. | Biotechnology | Director/Board Member Chief Executive Officer Director/Board Member | |
NovaSAID AB
NovaSAID AB Pharmaceuticals: MajorHealth Technology NovaSAID AB develops treatments for inflammation and pain in conditions such as rheumatoid arthritis. It discovers selective microsomal prostaglandin E synthase-1 (mPGES-1), and has also demonstrated its effect in animal models for pain and inflammation. The firm's approach is to prevent the pathological formation of prostaglandin E2 (PGE2) selectively, through the development of inhibitors of mPGES-1, the enzyme that is responsible for the formation of PGE2 during inflammation. Its mPGES-1 inhibition offers an approach for inhibiting pathological PGE2 production without adversely affecting other important prostanoids. The company was founded by Per-Johan Göte Jakobsson, Ralf Morgenstern, Bertil Samuelsson and Bengt Ingemar Samuelsson on October 26, 2004 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Comptroller/Controller/Auditor Chairman | |
OSSDSIGN AB | Medical Specialties | Director/Board Member Director/Board Member | |
Softhale NV
Softhale NV Miscellaneous Commercial ServicesCommercial Services Softhale NV engages in manufacturing medical, clinical and pharmaceutical equipment. The company was founded by Jurgen Rawert and Frank Bartels and is headquartered in Diepenbeek, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
ClanoTech AB
ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Rosetta Capital Ltd.
Rosetta Capital Ltd. Investment ManagersFinance Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London. | Investment Managers | Founder Private Equity Investor | |
winningtemp AB
winningtemp AB Packaged SoftwareTechnology Services Winningtemp AB provides personnel performance and development evaluation applications. It helps organizations and employees to interact together to achieve individual and collective goals. The company was founded by Mathias Hansson Fredlund and Pierre Lindmark in October 2014 and is headquartered in Gothenburg, Sweden. | Packaged Software | Chairman Director/Board Member | |
KDev Exploratory AB
KDev Exploratory AB Miscellaneous Commercial ServicesCommercial Services KDev Exploratory AB provides drug discovery solutions. It performs discovery research in various therapeutic areas, such as screening in oncology, neuroscience, lead finding, characterization in inflammation and angiogenesis/age-related macular degeneration. The company was founded by David Jern in 2000 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Director/Board Member Chief Administrative Officer | |
ANNEXIN PHARMACEUTICALS AB | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Mevia AB
Mevia AB Other Consumer ServicesConsumer Services Mevia AB provides drug package that helps patients manage their drug intake. It also provides intelligent solutions for medical treatments. The firm’s solutions address the greatest challenge in medical treatments improving adherence. The company also manages by increasing the patient support and providing personal adherence feedback in real time. Mevia works closely with their clients to develop innovative packaging and IT solutions that provide patients with the best possible experience. The company was founded by Linnea Olsson and Jesper Hassel and is headquartered in Gothenburg, Sweden. | Other Consumer Services | Chairman Director/Board Member | |
University of Oxford | College/University | Doctorate Degree Undergraduate Degree | |
MEDIVIR AB | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
Terrarock Ltd.
Terrarock Ltd. Engineering & ConstructionIndustrial Services Part of Terra Mauricia Ltd., Terrarock Ltd. is a Mauritian company that provides geotechnical solutions and wholesales drilling equipment. The company is based in Fond du Sac, Mauritius. | Engineering & Construction | Director/Board Member Director/Board Member | |
Recion Oy | Director/Board Member Director/Board Member | ||
Scibase AB | Director/Board Member Director/Board Member | ||
Mimir Capital AB
Mimir Capital AB Investment ManagersFinance Mimir Capital AB (Mimir Capital) is a private equity firm founded in 2013. The firm is headquartered in Stockholm, Sweden. | Investment Managers | Chairman Chief Executive Officer | |
OREXO AB | Pharmaceuticals: Major | Director of Finance/CFO Director of Finance/CFO | |
VOC Diagnostics AB
VOC Diagnostics AB Medical/Nursing ServicesHealth Services VOC Diagnostics AB is a cancer diagnostics firm focusing on detection of ovarian cancer as a first indication. The company was founded by György Horvath in 2017 and is headquartered in Solna, Sweden. | Medical/Nursing Services | Chairman Chief Executive Officer | |
Karolinska Institutet Holding AB
Karolinska Institutet Holding AB Investment Trusts/Mutual FundsMiscellaneous Part of Karolinska Institutet Holding AB, Nätverk Karolinska Institutet Science Park AB (KISP) facilitates interaction between academia and industry on Campus Solna. The company is based in Solna, Sweden. KISP collaborates closely with Karolinska Institutet, Akademiska Hus, and AWL to organize seminars, workshops, and networking events that help researchers, startups, and established companies connect and gain new insights. The CEO of the Swedish company is Karl Johan Ingvar Weigelt. | Investment Trusts/Mutual Funds | Chief Executive Officer General Counsel | |
ProNoxis AB
ProNoxis AB Pharmaceuticals: MajorHealth Technology ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden. | Pharmaceuticals: Major | Chairman Director/Board Member | |
ABLIVA AB | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Palette Life Sciences AB
Palette Life Sciences AB Medical SpecialtiesHealth Technology Palette Life Sciences AB operates as a pharmaceutical company. It specializes in developing products for local pain relief in obstetrics and gynecology. The company was founded by Berith Karlsson Tingåker, Gunvor Ekman-Ordeberg, Arne Folke Brodin and Lars Irestedt in 2009 and is headquartered in Solna, Sweden. | Medical Specialties | Director/Board Member Director of Finance/CFO | |
SCIBASE HOLDING AB (PUBL) | Medical Specialties | Director/Board Member Director/Board Member | |
Perma Ventures AB
Perma Ventures AB Investment ManagersFinance Perma Ventures AB provides financial advisory services. The private company is based in Stockholm, Sweden. | Investment Managers | Director/Board Member Director/Board Member | |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
TIANJIN BINHAI TEDA LOGISTICS (GROUP) CORPORATION LIMITED | Air Freight/Couriers | Director/Board Member Director/Board Member | |
Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd. | Director/Board Member Director/Board Member | ||
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Sino Biopharmaceutical Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is an innovative pharmaceutical group enterprise based in Lianyungang, China. Chia Tai Tianqing has six major product groups, including liver disease, anti-tumor, respiratory, infection, endocrine, and cardiovascular and cerebrovascular. The Chinese company invests heavily in innovative drug research and has high-level R & D platforms such as the national enterprise technology center. Chia Tai Tianqing is preparing for a number of products to enter the international market and actively undertakes corporate social responsibilities. The company was founded in 1969, and the CEO is Kang Xin Yu. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Beijing Tide Pharmaceutical Co., Ltd.
Beijing Tide Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Beijing Tide Pharmaceutical Co., Ltd. engages in research, development, manufacturing and sale of pharmaceutical products. The firm's products include kaifen flurbiprofen axetil injection, kaishi alprostadil injection, kaina beraprost sodium tablet and deyou pronase granules. The company was founded in May 1995 and is headquartered in Beijing, China. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Sino Biopharmaceutical (Beijing) Ltd.
Sino Biopharmaceutical (Beijing) Ltd. Miscellaneous Commercial ServicesCommercial Services Sino Biopharmaceutical (Beijing) Ltd. is an investment holding company. Its sole asset is its 33.6% interest in Beijing Tide Pharmaceutical Co., Ltd., a pharmaceutical company established in China with limited liability, which develops, manufactures, and market pharmaceutical products. Sino Biopharmaceutical (Beijing) was founded on December 31, 2007 and is headquartered in Hong Kong. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member |
Statistics
International
Sweden | 39 |
China | 5 |
United Kingdom | 4 |
Hong Kong | 3 |
Belgium | 2 |
Sectoral
Health Technology | 22 |
Consumer Services | 9 |
Commercial Services | 8 |
Finance | 6 |
Technology Services | 2 |
Operational
Director/Board Member | 299 |
Corporate Officer/Principal | 98 |
Chairman | 72 |
Chief Executive Officer | 42 |
Independent Dir/Board Member | 34 |
Most connected contacts
- Stock Market
- Insiders
- Johan Dighed
- Company connections